Jacobson Pharma Sustainability Profile
Jacobson Pharma Corporation Limited, commonly known as Jacobson Pharma, is a prominent player in the pharmaceutical industry, headquartered in Hong Kong (HK). Founded in 2015, the company has rapidly established itself as a leader in the development, manufacturing, and distribution of generic and proprietary pharmaceuticals across Asia and beyond. Specialising in a diverse range of therapeutic areas, Jacobson Pharma offers a unique portfolio of high-quality products, including prescription medications and over-the-counter solutions. The company is recognised for its commitment to innovation and quality, ensuring that its offerings meet stringent regulatory standards. With a strong market position, Jacobson Pharma has achieved significant milestones, including strategic partnerships and expansions that enhance its operational capabilities. As a trusted name in the pharmaceutical sector, Jacobson Pharma continues to focus on delivering effective healthcare solutions to improve patient outcomes.
DitchCarbon Score
How does Jacobson Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jacobson Pharma's score of 48 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Jacobson Pharma's reported carbon emissions
In 2025, Jacobson Pharma reported total carbon emissions of approximately 21,101,630 kg CO2e, comprising 1,196,010 kg CO2e from Scope 1, 19,645,690 kg CO2e from Scope 2 (market-based), and 259,930 kg CO2e from Scope 3. This marks a significant reduction from 2023, when emissions were about 63,219,040 kg CO2e, with Scope 1 emissions at 39,452,960 kg CO2e and Scope 2 at 23,612,700 kg CO2e. The company has set a near-term target to reduce electricity usage intensity by at least 3% across all facilities by FY2026, using FY2020 as a baseline. This commitment reflects Jacobson Pharma's focus on improving energy efficiency and reducing its carbon footprint. Jacobson Pharma's emissions data is not cascaded from any parent organization, indicating that the reported figures are independently sourced from Jacobson Pharma Corporation Limited. The company actively discloses its emissions across all three scopes, demonstrating transparency in its climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Scope 1 | 34,398,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 18,749,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 136,000 | 000,000 | 000,000 | 000,000 | 000,000 |
How Carbon Intensive is Jacobson Pharma's Industry?
How Carbon Intensive is Jacobson Pharma's Location?
Jacobson Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Jacobson Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
